Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages 3799-3806

  Farngren, Johan ^a   Persson, Margaretha ^a   Schweizer, Anja ^b   Foley, James E ^b   Ahreń, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBODY; C PEPTIDE; GLUCAGON; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HYDROCORTISONE; INCRETIN; INSULIN; NORADRENALIN; PLACEBO; POLYPEPTIDE; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; CELL FUNCTION; CLAMP; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMMON COLD; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; MONOTHERAPY; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADAMANTANE; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; NITRILES; PYRROLIDINES; YOUNG ADULT;

EID: 84867238377     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2332     Document Type: Article

References (35)

1. Baggio LL, Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157 (Pubitemid 46711096)
2. Kim W, Egan JM 2008 The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60:470-512
3. Nauck MA 2009 Unraveling the science of incretin biology. Eur J Intern Med 20(Suppl 2):S303-S308
4. Dunning BE, Foley JE, Ahrén B 2005 α-Cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48: 1700-1713 (Pubitemid 41317822)
5. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK 2011 Glucose-dependent inulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60:3103-3109
6. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894 (Pubitemid 41159387)
7. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE 2011 Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 13:775-783
8. Schweizer A, Couturier A, Foley JE, Dejager S 2007 Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetes. Diabet Med 24:955-961 (Pubitemid 47301637)
9. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE 2008 Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycemia. Diabetes Obes Metab 10:675-682 (Pubitemid 352044298)
10. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ 2007 Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30:890-895 (Pubitemid 46556583)
11. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S 2009 Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11:157-166
12. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S 2007 Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo controlled study. Diabetes Obes Metab 9:166-174 (Pubitemid 46206560)
13. Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S 2007 Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9:175-185 (Pubitemid 46206561)
14. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA 2008 Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 10:1047-1056
15. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S 2007 Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50:1148-1155 (Pubitemid 46701545)
16. Ahrén B, Foley JE, Bosi E 2011 Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 13:193-203
17. Keating GM 2010 Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 70:2089-2112
18. Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE 2009 Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 94:1236-1243
19. Cryer PE 1993 Glucose counterregulation: prevention and correction of hypoglycemia in humans. Am J Physiol 264:E149-E155 (Pubitemid 23077352)
20. Cryer PE 2012 Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039-1048
21. Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, Forsham PH 1975 Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 292:985-989
22. Foley JE, Ligueros-Saylan M, He YL, Holst JJ, Deacon CF, Dunning BE, Leone-Jones A, Yu T, Kelley DE 2008 Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 40:727-730
23. Ahrén B 2011 The future of incretin-based therapy-novel avenues - novel targets. Diabetes Obes Metab 13(Suppl 1):158-166
24. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P 2011 Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 165:77-84
25. Cryer PE 2002 Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45:937-948 (Pubitemid 34762188)
26. Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, Knop FK 2011 Regulation of glucagon secretion by incretins. Diabet Obes Metab 13(Suppl 1):89-94
27. de Heer J, Rasmussen C, Coy DH, Holst JJ 2008 Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263-2270
28. Bansal P, Wang Q 2008 Insulin as a physiological modulator of glucagon secretion. Am J Physiol 295:E751-E761
29. Havel PJ, Ahrén B 1997 Activation of eutonomic nervous and the adrenal medula contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. Diabetes 46: 801-807 (Pubitemid 27188257)
30. Taborsky Jr GJ, Mundinger TO 2012 Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 153:1055-1062
31. Schwartz TW, Holst JJ, Fahrenkrug J, Jensen SL, Nielsen OV, Rehfeld JF, de Muckadell OB, Stadil F 1978 Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 61:781-789
32. Gerich JE 1988 Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37:1608-1617 (Pubitemid 19004942)
33. Taborsky Jr GJ, Ahrén B, Havel PJ 1988 Autonomic mediation of glucagon secretion during hypoglycemia. Implications for impaired α-cell responses in type 1 diabetes. Diabetes 47:995-1005
34. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084 (Pubitemid 38619835)
35. Lukashevich V, Schweizer A, Foley J, Shao Q, Groop PH, Kothny W 2011 Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal renal impairment. Diabetologia 54(Suppl 1):S332-S333